
Oncology NEWS International
- Oncology NEWS International Vol 6 No 5
- Volume 6
- Issue 5
Breast Cancer Guide on CD-ROM Is Available
DENVER--The AMC Cancer Research Center, through its Center of Excellence in Health Communications, has developed The Personal Guide to Breast Cancer, a multimedia CD-ROM guide to breast cancer prevention, detection, treatment, and resources, designed to be understood by the average layperson.
DENVER--The AMC Cancer Research Center, through its Center of Excellencein Health Communications, has developed The Personal Guide to BreastCancer, a multimedia CD-ROM guide to breast cancer prevention, detection,treatment, and resources, designed to be understood by the average layperson.
"Audiovisual presentations with full-color photographs guide theviewer through the information, addressing common questions and concerns,"said Bob Baker, president and CEO of AMC.
It is available in English or Spanish, and for Windows or Macintosh.There is a version for home and office use ($29.95, order no. U7AAAO) anda touch-screen version for educational and public-use settings ($49.95,U7AAB8).
The guide is being marketed by Time Life, with a portion of the profitsgoing to AMC. Order by calling Time Life Customer Services at 1-800-846-3843.
Articles in this issue
about 29 years ago
Delaying Chemotherapy May Compromise Distant Controlabout 29 years ago
Precision Dosing a Reality with Intensity Modulated RTabout 29 years ago
Mammography's Predictive Value May Be Improvedabout 29 years ago
Oncology Administrators Must Plan for Transition in Mergersabout 29 years ago
Differentiation Agent Improves Myelodysplasia Survival Ratesabout 29 years ago
NCPB Hears From Several Cancer Groups on Policy Issuesabout 29 years ago
Guidelines Needed for Distress in Cancer Patientsabout 29 years ago
Skin Cancer Project Receives Recognitionabout 29 years ago
Few Patients Surveyed Regret Prophylactic Mastectomyabout 29 years ago
New Neupogen Formula More Temperature StableNewsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Related Content


TIP136 ELEGANT: Elacestrant Versus Standard Endocrine Therapy (ET) in Women and Men With Node-Positive, Estrogen Receptor–Positive (ER+), HER2-Negative (HER2–), Early Breast Cancer (eBC) With High Risk of Recurrence in a Global, Multicenter, Randomized, Open-Label Phase 3 Study

TIP137 ADELA: A Double-blind, Placebo-Controlled, Randomized Phase 3 Trial of Elacestrant + Everolimus Versus Elacestrant + Placebo in ER+/HER2- Advanced Breast Cancer (aBC) Patients With ESR1-Mutated Tumors Progressing on Endocrine Therapy (ET) + CDK4/6i

138 HER2CLIMB-05: A Randomized, Double-blind, Phase 3 Study of Tucatinib Versus Placebo Added to Trastuzumab and Pertuzumab as Maintenance Therapy for HER2+ Metastatic Breast Cancer















































